• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
-
Generic Name: lipid nanoparticles containing CRISPR/Cas12HF mRNA and a CRISPR RNA (crRNA) targeting the HAO1 gene
Date Designated: 09/20/2024
Orphan Designation: treatment of primary hyperoxaluria
Orphan Designation Status: Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Yoltech Therapeutics Co., Ltd
Room 1201, Building A, No.58, Tanzhu Rd, Minhang District
Shanghai
China

The sponsor address listed is the last reported by the sponsor to OOPD.

*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-